TORONTO, ONTARIO--(Marketwired - Jan. 8, 2014) - Revive Therapeutics Ltd. (TSX VENTURE:RVV) (formerly Mercury Capital II Limited (TSX VENTURE:MFF.P)) (the "Company") announced today that it has begun trading on the TSX Venture Exchange (the "TSXV") under the symbol "RVV" pursuant to the TSXV's Final Exchange Bulletin issued on January 7, 2014 in respect of Mercury Capital II Limited's Qualifying Transaction.

Information relating to the closing of the Qualifying Transaction including details of the transaction, management and board of directors was previously announced on January 6, 2014; to view this information, readers are directed to the Company's SEDAR profile at

About Revive Therapeutics Ltd.

Revive Therapeutics Ltd. is a Canadian public company (TSX VENTURE:RVV) focused on acquiring, developing and commercializing treatments for major market opportunities such as sleep apnea, gout and rare diseases. The Company aims to bring drugs to market by finding new uses for old drugs, also known as drug repurposing, and improving the therapeutic performance of existing drugs for underserved medical needs. Additional information on the Company is available at

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Revive Therapeutics Ltd.
Fabio Chianelli
Chief Executive Officer
905-605-5535 (ext. 10)